Endocrine Gland Disorders is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Endocrine Gland Disorders have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Endocrine Gland Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Endocrine Gland Disorders overview
Endocrine gland disorders are medical conditions that affect the function of the endocrine system, which is a network of glands that produce and release hormones that regulate many body processes. Some common endocrine disorders are diabetes, hyperthyroidism, hypothyroidism, Cushing’s disease, and polycystic ovary syndrome (PCOS). These disorders can result from various causes, such as tumors, genetic factors, hormonal imbalances, or autoimmune reactions. Endocrine disorders can cause symptoms such as weight changes, fatigue, mood swings, reproductive problems, and growth abnormalities. Endocrine disorders are diagnosed by blood tests that measure the levels of hormones or other markers in the bloodstream. Treatment options depend on the type and cause of the disorder, but may include medication, surgery, radiation therapy, or lifestyle changes.
For a complete picture of PTSR and LoA scores for drugs in Endocrine Gland Disorders, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
